Covid-19 Vaccination in India: An Exploratory Analysis

Sandip K. Agarwal and Maharnab Naha IISER Bhopal

January 2023

Abstract

Our study is designed to explore the patterns in covid vaccination coverage in India at the district level. We use data from the first six months of covid vaccination drive in India that we combine with several other administrative data to create a unique data set that facilitates heterogeneity analysis across different vaccination phases and districts. We find evidence of past reported infection rates positively correlated with higher first dose covid vaccination outcomes. Higher Deaths as a proportion of district population is associated with lower vaccination uptake but as a percentage of reported infection was positively correlated with first dose covid vaccination. Districts that on average had higher population burden per health centre also had lower covid vaccination rates. Vaccination rates were lower in rural areas relative to urban areas whereas the association with literacy rate was positive. A higher vaccination rate among the population with higher blood pressure and hypertension (one of the comorbidities with covid infection) was observed while vaccination rates were lower among pregnant women and breastfeeding mothers. Districts with higher percentage of children with complete immunisation were associated with higher percentage of wasted children.

Introduction

The adverse impacts of COVID-19 pandemic has been felt on all spheres of human life with unprecedented challenges to public health and the economy. Herd immunity has been the key to minimise disruptions caused due to the pandemic. Sooner the population acquires herd immunity, sooner human life and activity would restore to pre-pandemic levels [1, 2]. However, relying upon the natural process of building up herd immunity would have been slow that would have given room to a prolonged pandemic. For governments and policy makers around the world, mass inoculation against COVID-19 has been the inevitable response to tackle the pandemic [3, 4].

While scientists have developed vaccines for COVID-19 at unprecedented speed, the process of translating this discovery into a manufactured product on a large scale and making it available to the masses through an uninterrupted and efficient supply chain is an inevitable component of mass inoculation [5, 6]. Vaccine shortages due to limited manufacturing capacity or due to inefficiencies in the supply chain would adversely affect the vaccination drive. In addition, a successful and an effective vaccination campaign requires much more than the availability of a safe and effective vaccine. Availability of a vaccine does not mean that people will rush to get inoculated. Introduction of a new vaccine demands rigorous research surrounding psychological, social and political aspects to assess public trust in the vaccine as much as it demands scientific rigorous evidence on safety and efficacy of the vaccine [7, 8]. Therefore, the observed vaccination outcomes are a result of interaction between supply and demand for the vaccine - where either of inadequate demand or supply or both would lead to low vaccination rates.

In the context of vaccine demand, a delay in acceptance or refusal of vaccination despite availability of vaccination services has been defined as vaccine hesitancy [9]. In 2019, the World Health Organization (WHO) declared vaccine hesitancy as one of the top ten threats to public health. If vaccine hesitancy is timely addressed, this can avert an adverse public health outcome [10].

COVID-19 vaccination rates had been one of the lowest among the low-and-middle-income-countries (LMICs) [11, 12, 13]. As most LMICs relied upon other vaccine producing nations for the supply of COVID-19 vaccines, vaccination against COVID-19 had been slow due to inadequate supply of vaccines [14, 15]. In addition, a host of complicated demand driven issues surrounding vaccine hesitancy could have further contributed to low vaccination rates as evident from vaccine hesitancy or uptake surveys [16, 11, 17, 18, 19].

Among the LMICs, India is one of the few that produced covid vaccines domestically [20]. In the past decade, India has stood out to be one of the largest vaccine producers in the world with a share of around 60% of vaccine supplies to UNICEF [21, 22, 23, 24, 25, 26]. Covid vaccination campaign in India was one of the largest in the world [27, 28]. In comparison to other LMICs, the proportion of the Indian population vaccinated with covid vaccine along with the pace at which they were vaccinated had been phenomenal [29, 30, 31, 32]. In this article, we analyse the observed covid vaccination rates in India. Our research is built upon a novel data set that was created by combining several administrative data sets and COVID-19 data sets for India. While researchers have analysed the the district level covid infection and fatalities [33, 34], as far as we know, our study is the first one to provide a comprehensive analysis of covid vaccination rates at the district level across the various phases of covid vaccination and the various demographic, socio-economic and health factors associated with the observed vaccination rates. Most existing research studies that have analysed the regional variation in the observed covid vaccination rates in India, research has been mostly limited to the heterogeneity in vaccine rates at the state level or a particular state or district and for early phases of vaccination [35, 36, 37, 38]. Our research makes important contributions to the field of public health research by improving our understanding of factors that are associated with covid vaccination rates in India and in providing directions for future research. Our findings from the Indian covid vaccination drive can significantly contribute to learning of other LMICs regarding the vaccination programs [39].

Our article is organised as the following. Section 2 lays down the background for vaccination in India in general followed by specific details related to covid vaccination campaign in India including the timeline for covid vaccination. Section 3 describes the data and the methodology. Section 4 presents the result and discusses the findings with an attempt to link it with possible reasons that could have led to the findings. Section 5 concludes.

Background

India had set up the immunisation programme in the 1970s (later renamed as the Universal Immunization Program (UIP)) with the objective of providing life-saving vaccinations that would play a critical role in lowering India's children and neonatal mortality and morbidity rates. While, during the first decade of the UIP's operation, various immunisation coverage levels in India had reached 70-85%, there had been a decline in status since then [40].

Anti-vaccine sentiments in India had never been an organised anti-vaccine movement unlike the west. Prior to the UIP during British India and after independence few prominent Indian leaders who had mass appeal among the people were apprehensive of safety and efficacy of the vaccines or questioned the compatibility of vaccines with their religious beliefs. The UIP met with criticism from a section of elitists on account of being a relatively costly program for a poor country like India [41]. However, since its inception UIP has led to successfully eliminating polio and maternal and neonatal tetanus from India by 2015 [42]. There had been only few lone episodes of resistance to particular vaccines in relatively smaller pockets in India that caught international attention [43, 44].

Covid vaccination drive in India began on January 16, 2021 with two double-dose approved vaccines -Covidshield and Covax. Covid vaccination was voluntary, providing room for delays in accepting the vaccine or refusing to get vaccinated in spite of the availability of a vaccine. Covid Vaccination drive in India was rolled out in phases that prioritised the section of population to get vaccinated first who were at the highest risk of infection [45]. The timeline for the same has been depicted in figure 1.

Phase-1 between January 16 to February 28 covered vaccination of all frontline workers, who were actively involved in containing the spread of the pandemic. The frontline workers included health workers, security staff and people who provided essential services to the general public. During Phase-2 in March

2021, the population aged 60 years and above were eligible for vaccination. In addition, individuals aged 45 years and above with comorbidities like hypertension, diabetes, HIV infection etc. too were made eligible for vaccination during phase 2. Phase-3 in the month of April extended COVID-19 vaccination to all individuals aged 45 years and above. The last and the final phase-4 of the vaccination starting May 1 made all adults 18 years of age and above eligible for vaccination.



Figure 1: Reported infection rate, Death rate and First dose covid vaccination in India across different phases.

Data and Methodology

We used data from various secondary sources to create a unique data set at the district level that allowed us to investigate the trends in vaccination rates across different districts and vaccination phases. In addition, we also included several demographic and health indicator variables that were capable of explaining the variation in the observed vaccination rates.

We obtained district level data for daily covid vaccination numbers as well as daily deaths and daily reported caseload numbers from the Data Development Lab [46]. The daily district level data on vaccination numbers, caseloads and deaths were aggregated across the vaccination phases to facilitate a phase wise analysis of covid vaccination rates. The phase wise data on vaccination numbers, caseloads and deaths were further normalised with district level population to arrive at respective rates. Figure 2 plots the reported infection and fatalities for the entire country over time. The population data used for normalisation was sourced in from the Harvard population database (Dataverse) [47] which provides the latest approximation for all districts in India in 2020.



Figure 2: Reported covid infection rates and covid deaths in India over time

As a measure of district level health infrastructure, we used the data from the Rural Health Statistics (RHS) for the year 2020-21 from the Health Information Management System (HMIS) portal of India. The data consists of the number of sub health centres, primary health centres and community health centres in every district. We converted the primary and community health centres into equivalent units of sub-health centres in the ratio 1:6 and 1:24 to arrive at a comparable number of health centres in all districts ([48]). Using the total equivalent number of sub health centres, two health infrastructure variables were constructed. The first one measured the average burden on a sub-health centre in a district, which was computed by dividing the population in that district by the number of equivalent sub health centres in a district. The other infrastructure variable is a measure of distance captured by the infrastructure density, which is constructed by dividing the number of equivalent sub-health centres by geographical area of the district (i.e. number of sub-health centres per square kms). Higher the density in a district, it is likely that smaller would be the average distance travelled to access the health centre.

In addition to health infrastructure, we used several district level health and education indicators from the latest round of the National Family and Health Survey (NFHS) data, which was the fifth round that was collected between 2019-21. NFHS data is an important database that tracks health status over time and administrative units in India that has been collected every four to five years since 1992-93. Some of the notable variables from NFHS-5 that we included in our analysis includes child and maternal health and nutrition, years of schooling, family planning etc.

In the beginning of 2018, Govt. of India identified 117 most backward districts (and called them aspirational districts) based on a composite index that captured deprivation (25%), health (30%), education (15%) and infrastructure (30%) [49]. The aspirational districts program was aimed at reducing inter-district and inter-state disparity by bringing the state and the central governments together on various developmental schemes and promoting a healthy competition among the districts towards achievement of improved target outcomes. We also used a binary indicator for aspirational districts in our analysis.

In order to control for district specific heterogeneity in demographic and socio-economic indicators, we also used several related variables from the 2011 census of India that included rural population, literacy, gender, social and religious minority and population density as a percentage or proportion of district population in the census data.

We created a comprehensive district level data set using the variables from various data sources as described above. Table 1 in the appendix describes different variables that we used for our analysis and the secondary data source from which it was obtained. Multiple linear regression models were used for each vaccination phase with the proportion of population vaccinated with the first dose of vaccine during the given phase as the dependent variable. The phase wise regression tables are provided in table 7 and table 8 in section A.2 in the appendix. Columns P1-P4 in table 7 and 8 denote the vaccination phase whereas subscripts 1 and 2 for phase 4 denote the first and the second month of phase 4. The explanatory variables in table 7 regression included covid variables (i.e. caseload and death rates during each phase) and health infrastructure variables along with demographic and socio-economic variables. The regressions in table 8

also included indicators of health and education from the NFHS-5 data in addition to the explanatory variables used in table 7 regressions. We used state fixed effects to control for unobserved state specific effects. In addition, we also use robust standard errors clustered at the state level in order to account for error dependence within districts belonging to the same state. Best fit models reported in table 7 and 8 were selected based on adjusted R-squared values and measures of information criteria (ie. with lowest AICs and BICs).

Results and Discussion

Covid vaccines in India were provided free of charge to all. Despite that people might not perceive it to be costless due to several opportunity costs and unobserved psychological costs, lack of trust and uncertainty surrounding vaccination, which can lead to vaccine hesitancy. Vaccine hesitancy can be a major driver of low demand and subsequently lower vaccination rates in spite of the availability of a vaccine. Therefore, availability of a vaccine does not mean that people will rush to get inoculated. The observed vaccination rates are the outcome of a complex interaction between the supply as well as the demand for the vaccine, and just one component alone.

Reported infection rates in a district, while likely to be indicative of actual infection rates, were also confounded with covid testing efforts. Districts that implemented more rigorous covid testing were also likely to report a higher number of covid cases compared to districts that had lower covid testing rates. On the contrary, unlike reported infection rates, covid fatalities were far more closely associated with the actual infection rate and were unlikely to be influenced by covid testing efforts. Both covid reported infection and death rates were likely to be correlated with vaccination rates, and hence we include these variables in our regression.

For all vaccination phases, we observed vaccination rates to be positively correlated with reported infection rates in the preceding vaccination phase. This might be driven by higher awareness about covid among people in districts with higher reported infection rates either due to higher testing efforts or prevalence of actual higher infection rates around them. We also included reported infection rate for the current phase, which stood out to be positive and significant only during the first month of phase 4. The initial first month of phase 4 coincided with the deadly second wave of covid infections in India. Therefore, it might be possible that the current infection rates were salient in driving the decision to get vaccinated. The association between covid deaths and vaccination rates were significant for phase 1 and phase 4 only. While the coefficient was negative for deaths as proportion of district population, it was positive for deaths as proportion of reported infection rate for the above period.

The above discussion tries to think of possible reasons for the observed relationship between past and current reported infection and deaths, which tell a demand side story. However, it cannot be undermined that covid infection and deaths would have been one of the critical inputs in designing vaccine allocation to different districts. Vaccination rates would have been lower in districts that were constrained due to limited supply of vaccines. Since, we had analysed the aggregate vaccination rates during an entire phase instead of daily or weekly vaccination, it might not be unreasonable to assume that vaccine supply would have been less volatile during an entire phase than over a week or on a particular day. Therefore, while not impossible, it is less likely that a district would have faced severe supply constraints due to short supply of vaccine during the entire vaccination phase. Nonetheless, we would not attribute lower vaccination rates to low demand only but rather a combination of both demand and supply side factors [45, 50].

Health infrastructure burden was captured by the proportion of population covered per health centre. A lower burden is indicative of better health infrastructure and is positively associated with vaccination rates across all vaccination phases and the coefficient was significant except phase 1. Since phase 1 targeted vaccination of health workers and frontline workers, it was not surprising to not find a significant correlation between health infrastructure and vaccination rates across districts.

Covid vaccination was available only at vaccination sites on demand which implied that individuals had to travel to the vaccination centres to get vaccinated. Health infrastructure density measures the average number of health centres per square kilometre in a district. While a lower density indicates greater distance

from the health centre, we found inverse and significant correlation between health infrastructure density and covid vaccination rates in early phase 4. The beginning of phase 4 covid vaccination in India coincided with the deadly second wave (as can be seen in figure 1) with high covid infections and deaths along with multiple localised lockdowns, which adversely affected densely populated areas more severely. Given that population density and health infrastructure density are positively correlated, the above finding might not be surprising. Moreover, besides health centres, schools, community centres and other public places were also converted into vaccination centres. Therefore, the health infrastructure density variable might not be completely capturing the average distance to the vaccination centre as described.

With respect to different demographic and socio-economic variables, we did not find them to explain heterogeneity in the vaccination rates across districts during different vaccination phases except for phase 4. Vaccine attitudes are dynamic and evolve over time and space. Therefore, it was possible that these correlations could have emerged only during the fourth phase of vaccination, when India was hit by the deadly second wave of covid and the country witnessed the worst situation in the entire pandemic [51, 52, 53, 54, 55, 50, 56]. Vaccination rates were negatively correlated with higher proportion of rural population in a district but positively correlated with higher literacy rates. Covid vaccination campaigns in India required an online registration to get vaccinated during the period of our analysis. In addition, during the above period, the registration platform was only accessible in English. Therefore, appointment registration for covid vaccination required access to a smart phone and internet along with English literacy. These factors could be partly driving the relationship between literacy and vaccination. Population density too was positively correlated with higher vaccination rates. There is anecdotal evidence that suggested high vaccine hesitancy among the rural population during the beginning of the fourth phase, which aligns with the "co-incidence dragon" [Post hoc ergo propter hoc: after this, therefore because of this in the literature [9, 57]. As stated earlier, roll out of covid vaccination in India prioritised the section of the population most susceptible to covid infection and fatalities. This section of the population included the elderly and those with comorbidities who had been vaccinated with the first dose of covid vaccine but yet to be vaccinated with the second dose of covid vaccine. It is important to mention that covid vaccines in India and elsewhere were mostly two shot vaccines. High efficiency would require that both doses of vaccines be administered in order to provide protection against fatal infection. During the second covid wave which coincided with the early fourth phase of vaccination, several deaths occurred among the vaccinated people, who were mostly vaccinated with the first dose of covid vaccine. Anecdotal evidence suggests that this led to the belief that vaccines were deadly and caused deaths giving way to coincidence dragon bias, particularly in the rural areas [58, 59, 60, 61]. Nonetheless, we cannot assert that coincidence dragon bias led to a reduction in vaccination numbers during the fourth phase. Given the severity of the second wave of covid, it cannot be ruled out that vaccine distribution would have been prioritised in favour of urban and more densely populated regions to contain the spread of infection which too could have adversely affected the vaccination drive in the rural areas.

There were no compelling correlations between social and religious groups that can explain the heterogeneity in vaccination rates consistently. During phase 4 of vaccination, districts with a higher proportion of SC population had lower vaccination rates. Vaccination rates were lower among the districts with relatively higher muslim population during phase 2. However, during the second month of phase 4, vaccination outcomes were relatively higher in districts with higher muslim populations. For muslims, Ramadan, the holy month of fasting, coincided with the first month of phase 4. Therefore, it could be the case that vaccination uptake was higher among muslims once Ramadan concluded [62, 63, 64].

We found vaccination rates to be correlated with selected maternal health indicators. Higher maternal protection against neonatal tetanus was positively correlated with covid vaccination rates. During phase 4, districts that had higher pregnancy rates between the age of 15 and 19 years and higher percentage of children exclusively breastfed had lower vaccination rates. Women of child bearing age were eligible for vaccination during the fourth phase of vaccination, but lack of scientific evidence and clear communication surrounding potential side-effects of the vaccine on a pregnant or a breastfeeding woman could have driven this finding [65, 66, 67].

With respect to child health indicators, districts with a higher proportion of wasted children had lower vaccination rates. We also found positive and significant correlation between complete immunisation of children and covid vaccination rates during phase 3 and 4 of the vaccination [68, 69]. However, for given

complete immunisation levels, the correlation between polio vaccination and covid vaccination were negative. It is important to note that unlike all other vaccines in the complete immunisation schedule that are invasive, polio vaccines are oral vaccines. Hence, the negative correlation of covid vaccine with polio vaccine might be indicative of aversion towards invasive medical procedures that could have built some hesitancy around covid vaccine, which too was invasive. Moreover, adult vaccination is not common in India unlike child immunisation, which too could have created a resistance to get vaccinated [70].

A positive and significant correlation between covid vaccination rate and proportion of population on medication for blood pressure during phase 2 and phase 3 was observed. Since, blood pressure and hypertension was one of the identified co-morbidities associated with covid infection, covid vaccination rates could have been higher. We found some positive correlation between health insurance coverage and vaccination rates too. Vaccination rates were also higher in aspirational districts during the initial first two phases of vaccination.

We compiled district level data from various secondary sources at the district level that facilitated the warranted heterogeneity analysis. We would like to clearly state that the observed relationship in our analysis should not be interpreted as a causal relationship between vaccination rates and other explanatory variables. There might be some element of causality in our evidence, which would have been invaluable if it could be identified, a causal analysis is limited due to unavailability of requisite data. We also understand that there could be mismeasurement errors particularly with respect to covid variables due to significant underreporting, yet our analysis would be defensible unless there are systematic errors in measurement of variables. However, given all these limitations we make best efforts to bring the several pieces of data together to provide an exploratory analysis of covid vaccination in India.

Conclusion

Our study is an attempt to explain the variation in the observed covid vaccination rates across districts in India during the first six months of the covid vaccination drive. Vaccination decision being a complex interplay between demand and supply, observed vaccination outcome could be indicating a short supply or demand or interaction of both is difficult to identify the causal factors that can explain spatio-temporal heterogeneity in vaccination rates. Therefore, our analysis provides exploratory evidence surrounding vaccination rates based on which we build thoughtful insights and suggest possible reasons that could have led to the observed empirical relationships.

We use data from the first six months of covid vaccination drive in India that we combine with several other administrative data to create a unique data set that facilitates heterogeneity analysis across different vaccination phases and districts. We find evidence of past reported infection rates positively correlated with higher first dose covid vaccination outcomes. Higher Deaths as a proportion of district population is associated with lower vaccination. Districts that on average had higher population burden per health centre also had lower covid vaccination rates. Districts with higher rural populations had lower vaccination rates whereas the association with literacy rate was positive. A higher vaccination among the population with higher blood pressure and hypertension (one of the comorbidities with covid infection) was observed while observed vaccination rates were lower among a higher proportion of pregnant women and breastfeeding mothers. Districts with higher percentage of children with complete immunisation were associated with higher percentage of children with complete immunisation were associated with higher reported relatively higher percentage of wasted children.

Our research makes an important contribution to the area of vaccine research in the LMICs by using data from India that hosted the largest covid vaccination drive in the world. We uncover several associations between vaccination rates, health and demographic variables that provide insights, which can be used to design future research and investigations surrounding vaccinations in LMICs.

References

- Daniel Susskind and David Vines. The economics of the covid-19 pandemic: an assessment. Oxford Review of Economic Policy, 36:S1–S13, 2020.
- [2] Patrick Sturgis, Ian Brunton-Smith, and Jonathan Jackson. Trust in science, social consensus and vaccine confidence. *Nature Human Behaviour*, 5, 05 2021.
- [3] Haley E. Randolph and Luis B. Barreiro. Herd immunity: Understanding covid-19. *Immunity*, 52:737–741, 05 2020.
- [4] Arnaud Fontanet and Simon Cauchemez. Covid-19 herd immunity: where are we? Nature Reviews Immunology, 20:583–584, 09 2020.
- [5] Omna Sharma, Ali A. Sultan, Hong Ding, and Chris R. Triggle. A review of the progress and challenges of developing a vaccine for covid-19. *Frontiers in Immunology*, 11, 10 2020.
- [6] Olivier Wouters, Kenneth Shadlen, Maximilian Salcher-Konrad, Andrew Pollard, Heidi Larson, Yot Teerawattananon, and Mark Jit. Health policy challenges in ensuring global access to covid-19 vaccines: production, affordability, allocation, and deployment. *Health Policy*, 397, 02 2021.
- [7] Steven Black and Rino Rappuoli. A crisis of public confidence in vaccines, 2010.
- [8] Heidi J Larson, Louis Z Cooper, Juhani Eskola, Samuel L Katz, and Scott Ratzan. Addressing the vaccine confidence gap. The Lancet, 378:526–535, 08 2011.
- [9] Noni E. MacDonald, Jennifer Smith, and Mary Appleton. Risk perception, risk management and safety assessment: What can governments do to increase public confidence in their vaccine system? *Biologicals*, 40:384–388, 09 2012.
- [10] Heidi J. Larson, Caitlin Jarrett, William S. Schulz, Mohuya Chaudhuri, Yuqing Zhou, Eve Dube, Melanie Schuster, Noni E. MacDonald, and Rose Wilson. Measuring vaccine hesitancy: The development of a survey tool. *Vaccine*, 33:4165–4175, 08 2015.
- [11] Julio S Solís Arce, Shana S Warren, Niccolò F Meriggi, Alexandra Scacco, Nina McMurry, Maarten Voors, Georgiy Syunyaev, Amyn Abdul Malik, Samya Aboutajdine, Opeyemi Adeojo, et al. Covid-19 vaccine acceptance and hesitancy in low-and middle-income countries. *Nature medicine*, 27(8):1385–1394, 2021.
- [12] Hasan Mahmud Reza, Vaishnavi Agarwal, Farhana Sultana, Razmin Bari, and Ahmed Mushfiq Mobarak. Why are vaccination rates lower in low and middle income countries, and what can we do about it? *bmj*, 378, 2022.
- [13] Christopher Wolf, Alex Leeds Matthews, and Horus Alas. Wealthy countries are outpacing poor nations in covid-19 vaccination rates, 11 2022.
- [14] Matthew M. Kavanagh, Lawrence O. Gostin, and Madhavi Sunder. Sharing technology and vaccine doses to address global vaccine inequity and end the covid-19 pandemic. JAMA, 326, 07 2021.
- [15] Gregg S Gonsalves and Saad B Omer. Scale up production of covid-19 vaccines in lmics, 2022.
- [16] Jeffrey V. Lazarus, Scott C. Ratzan, Adam Palayew, Lawrence O. Gostin, Heidi J. Larson, Kenneth Rabin, Spencer Kimball, and Ayman El-Mohandes. A global survey of potential acceptance of a covid-19 vaccine. *Nature Medicine*, 27:225–228, 10 2020.
- [17] Arjun Kharel and Shana Warren. Is vaccine hesitancy a problem?, 2022.
- [18] Jeffrey V Lazarus, Katarzyna Wyka, Trenton M White, Camila A Picchio, Kenneth Rabin, Scott C Ratzan, Jeanna Parsons Leigh, Jia Hu, and Ayman El-Mohandes. Revisiting covid-19 vaccine hesitancy around the world using data from 23 countries in 2021. Nature communications, 13(1):3801, 2022.
- [19] Jeffrey V Lazarus, Katarzyna Wyka, Trenton M White, Camila A Picchio, Lawrence O Gostin, Heidi J Larson, Kenneth Rabin, Scott C Ratzan, Adeeba Kamarulzaman, and Ayman El-Mohandes. A survey of covid-19 vaccine acceptance across 23 countries in 2022. *Nature Medicine*, pages 1–10, 2023.

- [20] Ingrid T. Katz, Rebecca Weintraub, Linda-Gail Bekker, and Allan M. Brandt. From vaccine nationalism to vaccine equity — finding a path forward. New England Journal of Medicine, 384:1281–1283, 04 2021.
- [21] Sanjukta Sen Gupta, G. Balakrish Nair, Narendra Kumar Arora, and Nirmal Kumar Ganguly. Vaccine development and deployment: Opportunities and challenges in india. *Vaccine*, 31:B43–B53, 04 2013.
- [22] Edward M Choi. Covid-19 vaccines for low- and middle-income countries. Transactions of The Royal Society of Tropical Medicine and Hygiene, 03 2021.
- [23] T. V. Padma. India's covid-vaccine woes by the numbers. Nature, 04 2021.
- [24] Neeta Sanghi. How the modi government overestimated india's capacity to make covid vaccines, 04 2021.
- [25] Shailender Kumar. India in the global vaccine market prior to and during covid-19. *ISID: New Delhi*, *India*, 2022.
- [26] The Hindu. India supplies nearly 60% of vaccines used worldwide: Nirmala sitharaman, 07 2022.
- [27] Sanjeet Bagcchi. The world's largest covid-19 vaccination campaign. The Lancet Infectious Diseases, 21:323, 03 2021.
- [28] Om Prakash Choudhary, Priyanka Choudhary, and Indraj Singh. India's covid-19 vaccination drive: key challenges and resolutions. *The Lancet Infectious Diseases*, 0, 09 2021.
- [29] Leela Prasad. India vs rest of world: What the covid vaccine numbers say, 10 2021.
- [30] Covid vaccine: How many people has india vaccinated? BBC News, 03 2021.
- [31] Ashish K Jha. India's covid vaccination was one of most impressive in world: Dr ashish k jha, 11 2022.
- [32] India's vaccination drive outpaces most countries as it breaches 100 crore inoculation mark. The Economic Times, 09 2021.
- [33] Vandana Tamrakar, Ankita Srivastava, Nandita Saikia, Mukesh C. Parmar, Sudheer Kumar Shukla, Shewli Shabnam, Bandita Boro, Apala Saha, and Benjamin Debbarma. District level correlates of covid-19 pandemic in india during march-october 2020. PLOS ONE, 16:e0257533, 09 2021.
- [34] Dr. Debarshi Ghosh, Apurba Sarkar, and Dr. Pradip Chouhan. Covid-19 second wave: district level study of concentration and fatality in india. *Environmental Challenges*, page 100221, 07 2021.
- [35] Chiori Kodama, Gary Kuniyoshi, and Abdinasir Abubakar. Lessons learned during covid-19: Building critical care/icu capacity for resource limited countries with complex emergencies in the world health organization eastern mediterranean region. *Journal of Global Health*, 11, 07 2021.
- [36] Pritu Dhalaria, Himanshu Arora, Ajeet Kumar Singh, Mansi Mathur, and Ajai Kumar S. Covid-19 vaccine hesitancy and vaccination coverage in india: An exploratory analysis. *Vaccines*, 10:739, 05 2022.
- [37] Varun Vasudevan, Abeynaya Gnanasekaran, Bhavik Bansal, Chandrakant Lahariya, Giridara Gopal Parameswaran, and James Zou. Assessment of covid-19 data reporting in 100+ websites and apps in india. PLOS Global Public Health, 2:e0000329, 04 2022.
- [38] Ravi Mittal Mittal, Oommen C. Kurian, and Ravi. Bringing the covid-19 vaccine to every hamlet: The story of raigarh, 06 2022.
- [39] Bindu Shajan Perappadan. India's covid-19 vaccine pace is inspirational to lower income countries, says vaccine alliance official. *The Hindu*, 10 2021.
- [40] Vipin M. Vashishtha. Status of immunization and need for intensification of routine immunization in india. *Indian Pediatrics*, 49:357–361, 05 2012.
- [41] Niels Brimnes. Fallacy, sacrilege, betrayal and conspiracy: the cultural construction of opposition to immunisation in india, 2017.

- [42] Sophie Cousins. India is declared free of maternal and neonatal tetanus, 2015.
- [43] G. Mudur. Antivaccine lobby resists introduction of hib vaccine in india. *BMJ*, 340:c3508–c3508, 06 2010.
- [44] K. B. Saxena, D. Banerji, I. Qadeer, N. J. Kurian, R. Priya, M. Shiva, J. Puliyel, and G. Dabade. "antivaccine lobby" replies to the bmj. BMJ, 341:c4001-c4001, 07 2010.
- [45] Neha Purohit, Yashika Chugh, Pankaj Bahuguna, and Shankar Prinja. Covid-19 management: The vaccination drive in india. *Health Policy and Technology*, 11:100636, 06 2022.
- [46] Sam Asher, Tobias Lunt, Ryu Matsuura, and Paul Novosad. Development research at high geographic resolution: An analysis of night lights, firms, and poverty in india using the shrug open data platform. *Policy Research Working Papers*, 02 2021.
- [47] Weiyu Wang, Rockli Kim, and S V Subramanian. Population Estimates for Districts and Parliamentary Constituencies in India, 2020, 2021.
- [48] Rural Health Statistics, 2020-21. Government of India Ministry of Health and Family Welfare Statistics Division, 05 2022.
- [49] NITI Aayog. Aspirational districts: Unlocking potentials. New Delhi: NITI Aayog, Government of India, 2018.
- [50] Udani Samarasekera. India grapples with second wave of covid-19. The Lancet Microbe, 2:e238, 06 2021.
- [51] The Lancet. India's covid-19 emergency. The Lancet, 397:1683, 05 2021.
- [52] Yamini Aiyar, Vijay Chandru, Mirai Chatterjee, Sapna Desai, Armida Fernandez, Atul Gupta, Gagandeep Kang, Tarun Khanna, Kiran Mazumdar-Shaw, Nachiket Mor, Arnab Mukherji, Poonam Muttreja, Thelma Narayan, Bhushan Patwardhan, K. Sujatha Rao, Sharad Sharma, Devi Shetty, S. V. Subramanian, Leila E. Caleb Varkey, Sandhya Venkateswaran, and Vikram Patel. India's resurgence of covid-19: urgent actions needed. *The Lancet*, 0, 05 2021.
- [53] Saurabh Kumar. Second wave of covid-19: Emergency situation in india. Journal of Travel Medicine, 05 2021.
- [54] Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, Govindasamy Agoramoorthy, and Sang-Soo Lee. The current second wave and covid-19 vaccination status in india. *Brain, Behavior,* and Immunity, 96:1–4, 08 2021.
- [55] Kamala Thiagarajan. Why is india having a covid-19 surge? BMJ, 373:n1124, 04 2021.
- [56] Arnab Sarkar, Alok Kumar Chakrabarti, and Shanta Dutta. Covid-19 infection in india: A comparative analysis of the second wave with the first wave. *Pathogens*, 10:1222, 09 2021.
- [57] Robert M. Jacobson, Paul V. Targonski, and Gregory A. Poland. A taxonomy of reasoning flaws in the anti-vaccine movement. *Vaccine*, 25:3146–3152, 04 2007.
- [58] Soniya Agrawal. Actor's death fuels vaccine hesitancy in tamil nadu amid covid surge, misinformation adds fire, 05 2021.
- [59] Rehan Mustafa. Villagers jump into river in up's barabanki to escape covid vaccination, 05 2021.
- [60] Mausami Singh, Abhishek Mishra, Ravish Pal Singh, and Rohit Kumar Singh. 'those who take the jab die': Rumours mar covid vaccination drive in rural india, 06 2021.
- [61] Santa Nibedita and Nadeem Sultan. Covid-19: Vaccination rumours afflict mp villages, frontline workers face the brunt, 05 2021.
- [62] Sarah N Ali, Wasim Hanif, Kiran Patel, and Kamlesh Khunti. Ramadan and covid-19 vaccine hesitancy—a call for action. *The Lancet*, 04 2021.

- [63] Nusrat-E Mozid, Mohammad Ashraful Amin, Shirin Shahadat Jhumur, Imran Hossain Monju, Sanjana Binte Ahmed, Shakila Sharmin, Wharesha Sarker, and Mohammad Delwer Hossain Hawlader. Covid-19 risk of infection and vaccination during ramadan fasting: knowledge and attitudes of bangladeshi general population. *Heliyon*, 7:e08174, 10 2021.
- [64] Naghma Sahar. Muslim clergy must spread the message loud covid vaccine won't invalidate ramzan fast, 04 2021.
- [65] Nadia G. Diamond-Smith, Preetika Sharma, Mona Duggal, Navneet Gill, Jagriti Gupta, Vijay Kumar, Jasmeet Kaur, Pushpendra Singh, Katy Bradford Vosburg, and Alison M. El Ayadi. The supply is there. so why can't pregnant and breastfeeding women in rural india get the covid-19 vaccine? *PLOS Global Public Health*, 2:e0001321, 12 2022.
- [66] Archana Kumari, Reeta Mahey, Garima Kachhawa, Rajesh Kumari, and Neerja Bhatla. Knowledge, attitude, perceptions, and concerns of pregnant and lactating women regarding covid-19 vaccination: A cross-sectional survey of 313 participants from a tertiary care centre of north india. *Diabetes Metabolic Syndrome: Clinical Research Reviews*, 16:102449, 03 2022.
- [67] Sneha Shashidhara and Mukherjee Shagata Barnhardt, Sharon. Covid-19 vaccination status and hesitancy: Survey evidence from rural india. Centre for Social and Behaviour Change, Ashoka University, Working Paper, 11, 12 2022.
- [68] Nijika Shrivastwa, Brenda W. Gillespie, Giselle E. Kolenic, James M. Lepkowski, and Matthew L. Boulton. Predictors of vaccination in india for children aged 12-36 months. *Vaccine*, 33 Suppl 4:D99–105, 11 2015.
- [69] Nijika Shrivastwa, Abram Wagner, and Matthew Boulton. Analysis of state-specific differences in childhood vaccination coverage in rural india. *Vaccines*, 7:24, 02 2019.
- [70] Janamarie M. Perroud, Shad Soldano, Anton L.V. Avanceña, and Abram Wagner. Adult vaccination uptake strategies in low- and middle-income countries: A systematic review. *Vaccine*, 08 2022.

Appendix

A1.Summary Statistics

Var	\mathbf{Sdev}	\mathbf{Min}	Median	Mean	Max	\mathbf{Obs}
lit_p	10.529	28.772	61.773	62.075	88.737	729.000
${f muslim_p}$	17.004	0.225	7.186	12.339	98.515	729.000
hh_rural_p	21.371	0.000	80.365	74.125	100.000	729.000
php_3	72.735	755.000	1016.000	1021.704	1332.000	729.000
pop_den	4779.987	1.509	421.074	1145.098	82844.829	729.000
php_{-2}	5.269	16.000	25.300	26.355	50.600	729.000
$\mathrm{php}_{-}12$	23.051	1.200	35.700	40.209	97.800	729.000
php_8	9.056	41.200	96.900	93.556	100.000	729.000
$\mathrm{php}_{-}13$	10.329	0.000	9.800	12.645	52.900	729.000
mch_{-3}	6.222	55.100	92.600	91.069	100.000	729.000
\mathbf{cvv}_{-1}	15.670	0.000	77.500	76.255	100.000	729.000
\mathbf{cvv} _4	14.824	0.000	81.900	80.029	100.000	729.000
$hinfra_p$	1573.891	178.686	2556.745	2767.873	21045.168	727.000
hinfra_a	1.058	0.001	0.170	0.323	21.762	727.000
$\mathbf{st}_{-}\mathbf{p}$	28.368	0.000	4.827	19.301	99.421	729.000
sc_p	9.303	0.000	15.506	14.620	50.170	729.000
adistrict	0.370	0.000	0.000	0.163	1.000	729.000
cfp_{-3}	18.935	1.100	34.000	34.928	76.500	729.000
\cos_2	14.049	13.600	39.300	40.360	88.200	729.000
maf_1	12.680	0.000	18.600	20.633	80.900	729.000
maf_3	6.538	0.000	4.900	6.485	91.900	729.000
htw_3	5.219	8.500	21.100	21.472	42.100	729.000
cfn_2	33.473	0.000	55.000	41.246	94.000	729.000
cfn_8	6.514	4.500	18.000	18.450	48.000	729.000

Table 1: Demographic and health data variables

Var	\mathbf{Sdev}	\mathbf{Min}	Median	Mean	Max	\mathbf{Obs}
$case_tp$	0.117	-0.003	0.006	0.035	1.478	629.000
case_cu	0.676	0.000	0.440	0.639	6.045	629.000
$deth_cu$	0.011	0.000	0.004	0.008	0.111	629.000
$deth_case_cu$	0.839	0.000	1.052	1.184	4.988	625.000

Table 2: Phase 1 Cowin data variables

Var	\mathbf{Sdev}	\mathbf{Min}	Median	Mean	Max	Obs
case_tp	0.131	0.000	0.009	0.054	1.475	629.000
case_cu	0.745	0.000	0.450	0.674	7.007	629.000
$deth_cu$	0.011	0.000	0.004	0.008	0.114	629.000
$deth_case_cu$	0.818	0.000	1.041	1.174	4.989	626.000

Table 3: Phase 2 Cowin data variables

Var	\mathbf{Sdev}	\mathbf{Min}	Median	Mean	\mathbf{Max}	\mathbf{Obs}
case_tp	1.215	0.000	0.722	1.113	9.664	629.000
case_cu	0.816	0.000	0.477	0.728	7.356	629.000
$\mathbf{deth}_{-}\mathbf{cu}$	0.012	0.000	0.004	0.008	0.116	629.000
$deth_case_cu$	0.728	0.000	1.026	1.112	4.270	626.000

Table 4: Phase 3 Cowin data variables

Var	\mathbf{Sdev}	\mathbf{Min}	Median	Mean	Max	Obs
$case_tp$	0.693	0.000	0.421	0.642	8.183	629.000
case_cu	2.013	0.000	1.184	1.841	17.020	629.000
$deth_cu$	0.015	0.000	0.006	0.011	0.130	629.000
deth_case_cu	0.375	0.000	0.562	0.593	2.414	626.000

Table 5: Phase 4.1 Cowin data variables

Var	\mathbf{Sdev}	\mathbf{Min}	Median	Mean	Max	\mathbf{Obs}
$case_tp$	0.289	0.000	0.058	0.183	2.609	629.000
case_cu	2.560	0.000	1.700	2.483	20.299	629.000
$deth_cu$	0.023	0.000	0.010	0.019	0.159	629.000
$deth_case_cu$	0.490	0.000	0.722	0.789	3.768	626.000

Table 6: Phase 4.2 Cowin data variables

A2.Regressions

	Dependent variable: pdos1					
	(P1)	(P2)	(P3)	$(P4_{1})$	$(P4_2)$	
st_p	0.01^{***} (0.001)					
hh_rural_p				-0.03^{***} (0.01)	-0.03^{**} (0.01)	
lit_p			0.08^{***} (0.01)	0.03^{***} (0.01)	0.09^{***} (0.02)	
php_3		0.002^{**} (0.001)	0.003^{**} (0.001)			
sc_p					-0.06^{**} (0.02)	
muslim_p		-0.01^{**} (0.005)			0.04^{***} (0.01)	
pop_den			0.0002^{***} (0.0001)		0.001^{***} (0.0002)	
hinfra_p		-0.0002^{***} (0.0000)	-0.0003^{***} (0.0001)	-0.0002^{***} (0.0001)	-0.001^{***} (0.0001)	
hinfra_a					-4.69^{***} (1.03)	
case_cu	0.67^{***} (0.05)	1.16^{***} (0.10)	2.04^{***} (0.15)	0.19^{***} (0.06)	1.54^{***} (0.15)	
deth_cu	-12.69^{***} (3.28)				$-80.44^{***} \\ (15.65)$	
deth_case_cu	0.09^{**} (0.04)			-0.87^{***} (0.24)	1.25^{***} (0.47)	
case_tp				0.81^{***} (0.20)		
Constant	-0.03 (0.13)	-0.32 (1.03)	-5.83^{***} (1.70)	$\begin{array}{c} 4.36^{***} \\ (0.99) \end{array}$	2.54 (2.16)	
State FE	Yes	Yes	Yes	Yes	Yes	
$\begin{array}{c} \text{Observations} \\ \text{AIC} \\ \text{BIC} \\ \text{R}^2 \\ \text{Adjusted } \text{R}^2 \end{array}$	$\begin{array}{c} 625 \\ 604.79 \\ 751.23 \\ 0.64 \\ 0.62 \end{array}$	$\begin{array}{c} 629 \\ 2030.32 \\ 2190.3 \\ 0.70 \\ 0.68 \end{array}$	$\begin{array}{c} 629 \\ 2561.77 \\ 2726.2 \\ 0.78 \\ 0.77 \end{array}$	$\begin{array}{r} 626 \\ 2279.99 \\ 2439.81 \\ 0.66 \\ 0.65 \end{array}$	$\begin{array}{r} 626\\ 3195.05\\ 3372.62\\ 0.72\\ 0.71\end{array}$	

Table 7: Regression table without the NFHS data variables

		Deper	ndent variable:	pdos1	
	(P1)	(P2)	(P3)	$(P4_{1})$	$(P4_2)$
st_p	0.01^{***} (0.001)		-0.01^{***} (0.005)		
lit_p					$\begin{array}{c} 0.12^{***} \\ (0.02) \end{array}$
females per 1,000 males					-0.01^{***} (0.002)
sc_p					-0.07^{***} (0.02)
muslim_p		-0.01^{***} (0.005)			0.04^{***} (0.01)
adistrict	$\begin{array}{c} 0.15^{***} \\ (0.05) \end{array}$	0.31^{**} (0.14)			
hh_rural_p				-0.04^{***} (0.01)	
pop_den					$\begin{array}{c} 0.001^{***} \\ (0.0002) \end{array}$
hinfra_p		-0.0002^{***} (0.0000)	-0.0003^{***} (0.0001)	-0.0002^{***} (0.0001)	-0.001^{***} (0.0001)
hinfra_a					-3.81^{***} (1.02)
case_cu	0.61^{***} (0.05)	1.09^{***} (0.10)	$2.03^{***} \\ (0.15)$	$\begin{array}{c} 0.34^{***} \\ (0.09) \end{array}$	1.53^{***} (0.14)
deth_cu	-11.16^{***} (3.20)			-26.52^{**} (10.58)	-72.47^{***} (15.42)
deth_case_cu	0.08^{**} (0.04)	$\begin{array}{c} 0.02 \\ (0.09) \end{array}$	$0.09 \\ (0.16)$	-0.38 (0.29)	$\frac{1.33^{***}}{(0.47)}$
Population ≤ 15 years	-0.02^{***} (0.01)				
case_tp				$\begin{array}{c} 0.77^{***} \\ (0.19) \end{array}$	
HH with health insurance	0.01^{***} (0.002)			0.02^{**} (0.01)	0.05^{***} (0.02)
Female sterilization	-0.01^{***} (0.002)				

=

Dependent variable: pdos1						
(P1)	(P2)	(P3)	$(P4_{1})$	$(P4_2)$		
	0.02^{**} (0.01)					
	-0.02^{***} (0.01)					
		0.05^{***} (0.01)				
				0.09^{***} (0.02)		
				-0.13^{***} (0.05)		
				0.05^{*} (0.03)		
		0.05^{**} (0.02)		0.08^{**} (0.04)		
		-0.06^{**} (0.02)		-0.10^{**} (0.04)		
	0.07^{***} (0.01)	0.10^{***} (0.02)				
			-0.01^{***} (0.002)			
			-0.05^{***} (0.01)			
$\begin{array}{c} 0.21 \\ (0.29) \end{array}$	-1.72^{*} (0.98)	-1.10 (0.87)	5.40^{***} (0.94)	-2.50 (3.96)		
Yes	Yes	Yes	Yes	Yes		
$625 \\ 571.81 \\ 736.01 \\ 0.66$	$\begin{array}{c} 626 \\ 1996.14 \\ 2164.84 \\ 0.71 \end{array}$	626 2527.83 2696.52 0.79	626 2255.96 2429.1 0.68	$\begin{array}{r} 626\\ 3174.98\\ 3379.19\\ 0.74 \end{array}$		
	(P1) 0.21 (0.29) Yes 625 571.81 736.01 0.66	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		

Table 8: Regression tables with the NFHS data variables